Volume : 09, Issue : 11, November – 2022
Title:
26.A RESEARCH STUDY ON THE CHRONIC KIDNEY DISEASE AND MEASUREMENT OF FREQUENCY OF HYPERTENSION ON THESE PATIENTS
Authors :
Asad ur Rahman, Mansoor Ali, Sana Zeekash
Abstract :
Aim: Aim of the research is to measure the Frequency of Hypertension in chronic kidney disease patients.
Methods: This research study was conducted in 2020 in PAEC General Hospital Islamabad. Researchers investigated 453 hypertensive CKD individuals under nephrology care in the future. By incorporating 24-h ABP having RH prognosis (office BP 130/80 mm Hg notwithstanding compliance to 4 full dose antihypertensive drugs along with the diuretic agent or 4 drugs), four organizations were made: control (ABP 127/78 mm Hg deprived of RH); pseudo-opposition (ABP 125/75 mm Hg through RH); sustained hypertension; in addition, true resistance. Our current research was conducted from 1st Aug 2020 to 31st Oct 2020. The survival analyses’ endpoints included renal (end-stage renal illness or mortality) also cardiovascular problems.
Results: Age has been 63 + 15 years, males 59%, diabetes 38%, cardiovascular illness 32%, median proteinuria 0.25 (interquartile range 0.08 to 0.85) g/day, projected glomerular filtration rate 45 + 21 ml/min/1.74 m2, and 24-h ABP 128 + 18/73 + 11 mm Hg. Individuals having true resistance comprised 23.8%, and pseudo-resistant individuals comprised 8.2%, although those who had hypertension were 44.8%, and control individuals were 28.2%. During the 58-month follow-up period, 113 cardiovascular events and 168 renal incidents happened. In comparison to control participants, cardiovascular danger (hazard ratio [96% CI]) remained 1.25 (0.56 to 3.75) in pseudo resistance, 1.12 (0.68 to 1.85) in persistent hypertension, in addition 2.97 (2.15 to 4.45) in serious resistance. The corresponding renal incident risks were 1.19 (0.45 to 4.14), and 3.16.
Conclusion: Pseudo resistant in CKD is not related through enlarged cardio-renal danger, also chronic hypertension predicts the solitary actual consequence. Accurate resistivity remains common also distinguishes persons at high cardiovascular risk.
Keywords: Frequency, Hypertension, chronic kidney disease (CKD).
Cite This Article:
Please cite this article in press Asad ur Rahman et al, A Research Study On The Chronic Kidney Disease And Measurement Of Frequency Of Hypertension On These Patients.,Indo Am. J. P. Sci, 2022; 09(11).
Number of Downloads : 10
References:
1. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;1212:2032–45.
2. International Diabetes Federation. IDF Diabetes Atlas. 10th ed. 2021.
3. Li L, Sun N, Zhang L, Xu G, Liu J, Hu J, et al. Fast food consumption among young adolescents aged 12–15 years in 54 low- and middle-income countries. Glob Health Action. 2020;131:1795438.
4. Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;38910085:2239–51.
5. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;871:4–14.
6. Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, et al. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;943:567–81.
7. Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2016;51:49–56.
8. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clinical research ed). 2000;3217258:405–12
9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ (Clinical research ed). 1998;3177160:703.
10. Molitch ME, Adler AI, Flyvbjerg A, Nelson RG, So WY, Wanner C, et al. Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int. 2015;871:20–30.
11. Wilson JM. Jungner YG [Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam. 1968;654:281–393.
12. Internation Diabetes Foundation. IDF Diabetes Atlas. 9th ed. 2019.
13. Mills KT, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, Chen J, He J. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney Int. 2015;885:950–7.
14. Tolossa T, Fetensa G, Regassa B, Yilma MT, Besho M, Fekadu G, Wakuma B, Bekele D, Mulisa D. Burden and determinants of chronic kidney disease among diabetic patients in Ethiopia: A systematic review and meta-analysis. Public Health Rev. 2021;42:1603969.
15. Shrestha DB, Budhathoki P, Sedhai YR, Baniya R, Gaire S, Adhikari Y, Marasini A, Bhandari S, Sedhain A. Prevalence of chronic kidney disease, its risk factors and outcome in Nepal: a systematic review and meta-analysis. J Nepal Health Res Counc. 2021;192:230–8.
16. Azeez T, Efuntoye O, Abiola B, Adeyemo S, Adewale B. The burden of diabetic kidney disease in Nigeria − systematic review and meta-analysis. J Egypt Soc Nephrol Transplant. 2021;214:194–202.
17. Loh PT, Toh MP, Molina JA, Vathsala A. Ethnic disparity in prevalence of diabetic kidney disease in an Asian primary healthcare cluster. Nephrology (Carlton). 2015;203:216–23.
18. Kaze AD, Ilori T, Jaar BG, Echouffo-Tcheugui JB. Burden of chronic kidney disease on the African continent: a systematic review and meta-analysis. BMC Nephrol. 2018;191:125.
19. Shrestha N, Gautam S, Mishra SR, Virani SS, Dhungana RR. Burden of chronic kidney disease in the general population and high-risk groups in South Asia: a systematic review and meta-analysis. PLoS ONE. 2021;1610: e0258494.
20. Halle MP, Kengne AP, Ashuntantang G. Referral of patients with kidney impairment for specialist care in a developing country of sub-Saharan Africa. Ren Fail. 2009;315:341–8.
21. Yaqub S, Kashif W, Raza MQ, Aaqil H, Shahab A, Chaudhary MA, Hussain SA. General practitioners’ knowledge and approach to chronic kidney disease in Karachi. Pakistan Indian J Nephrol. 2013;233:184–90.
22. Szczech LA, Stewart RC, Su HL, DeLoskey RJ, Astor BC, Fox CH, McCullough PA, Vassalotti JA. Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). PLoS ONE. 2014;911: e110535.
23. Valencia WM, Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ (Clinical research ed). 2017;356: i6505.
24. Centers for Disease Control and Prevention. Incidence of end-stage renal disease among persons with diabetes–United States, 1990–2002. MMWR Morb Mortal Wkly Rep. 2005;5443:1097–100.
25. Bello AK, Levin A, Tonelli M, Okpechi IG, Feehally J, Harris D, et al. Assessment of global kidney health care status. JAMA. 2017;31718:1864–81.
26. Htay H, Alrukhaimi M, Ashuntantang GE, Bello AK, Bellorin-Font E, Benghanem Gharbi M, et al. Global access of patients with kidney disease to health technologies and medications: findings from the Global Kidney Health Atlas project. Kidney Int Suppl. 2011;2018(82):64–73.
27. Endocrinology TLD. Forging paths to improve diabetes care in low-income settings. Lancet Diabetes Endocrinol. 2017;58:565.
28. Chow CK, Ramasundarahettige C, Hu W, AlHabib KF, Avezum A Jr, Cheng X, et al. Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. Lancet Diabetes Endocrinol. 2018;610:798–808.